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ABSTRACT
Human induced pluripotent stem cell-derived mesenchymal stem cells (iPS-
MSCs) are emerging as attractive options for use in cell replacement therapy, but 
their effect in kidney diseases remains unknown. Here, we showed that intravenous 
injection of iPS-MSCs protect against renal function loss in both short-term and 
long-term models of adriamycin nephropathy (AN). In the short-term AN model, 
iPS-MSCs conferred a substantial anti-apoptotic effect on tubular cells, associated 
with a downregulation of Bax and Bax/Bcl2 ratio and an upregulation of survivin 
expression. In vitro, conditioned medium from iPS-MSCs (iPSMSC-CM) significantly 
limited albumin-induced tubular apoptosis and enhanced tubular proliferation, 
accompanied by a reduced expression of tubular Bax and an elevated expression 
of Bcl2 and survivin. Oxidative stress was markedly attenuated by iPS-MSCs both 
in AN mice and in protein-overloaded tubular cells. In the long-term AN model, 
repeated injections of iPS-MSCs significantly inhibited tubulointerstitial fibrosis and 
reduced intrarenal deposition of collagen I, collagen IV and αSMA. Modulation of the 
hedgehog signaling pathway contributed to the anti-fibrotic effect of iPS-MSCs in 
chronic AN. Finally, we detected that most of the infused iPS-MSCs were entrapped 
in the lungs. In conclusion, our data support a beneficial role of iPS-MSCs in both 
acute and chronic AN.
INTRODUCTION
The worldwide prevalence of chronic kidney disease 
(CKD) has reached epidemic proportions over the last 
two decades. In Hong Kong, Renal Registry data from the 
Central Renal Committee of Hong Kong reported that the 
incidence of treated end-stage kidney disease (ESRD) has 
risen from 95 pmp in 1996 to 150 pmp in 2013 [1]. Despite 
the global epidemic of CKD documented in many countries 
and the rising costs of treating patients with ESRD, 
advances in the treatment of CKD have been rather modest. 
Conventional management including prescription of anti-
hypertensive and anti-proteinuric drugs plus stringent 
glycemic control may not adequately retard the progression 
of CKD to ESRD. Many patients progress inexorably 
towards ESRD and cardiovascular (CV) complications 
despite optimal medical therapy. On the other side, acute 
kidney injury (AKI) affects millions of people per year yet 
no therapeutic intervention has been shown to prevent the 
different forms of AKI or accelerate recovery from injury 
[2]. Novel therapeutic approaches for all forms of human 
kidney disease are desperately needed.
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The advent of human induced pluripotent stem cell 
(iPS) technology brings new hope for ESRD patients 
who are on the long kidney transplant waiting list [3, 
4]. Over the past decade, however, slow progress 
has been made toward the clinical implementation 
of iPS cells on treating kidney diseases. There are a 
number of unresolved issues surrounding translational 
research using iPS cells, among which the high risk 
of tumorigenicity and unforeseeable spontaneous 
differentiation of the transplanted cells stand out [5]. 
Pre-differentiation of iPS cells into adult multipotent 
stem cells with less proliferation capacity and restricted 
differentiation potential prior to transplantation might be 
a robust alternative approach to leverage its strengths and 
minimize its safety concerns. To this end, a plethora of 
successful cases has been reported in pre-clinical settings 
[6–8]. Of those iPS derivatives reported, mesenchymal 
stem cells derived from iPS cells (iPS-MSCs) might be 
the most attractive cell type for treating kidney diseases, 
given all current documented data invariably pointing 
to a beneficial role of MSCs from various sources in 
preventing kidney injuries [9, 10]. Unlike traditional 
MSCs whose accessibility are very limited due to the 
tedious MSC procurement procedure and the paucity of 
MSC population in the tissue, the source of iPS-MSCs 
are inexhaustible because iPS cells can theoretically be 
induced from any somatic cells in the body and they 
display unlimited proliferation capacity. Currently, no 
studies have yet been conducted to systemically examine 
the effect of iPS-MSCs on kidney diseases, despite their 
great success in treating other diseases, including hind-
limb ischemia [11, 12], periodontitis/periodontal defect 
[13, 14], allergic airway inflammation [15], cigarette 
smoke-induced lung damage [16] cardiomyopathy [17] 
and bone defect [18].
To evaluate the therapeutic potential of human 
iPS-MSCs on AKI and CKD, we created a short-term 
adriamycin-induced nephropathy (AN) model featuring 
acute tubular injury and a long-term AN model with 
intrarenal fibrotic changes that resemble human CKD 
in immunodeficient mice. Our data support a protective 
role of iPS-MSCs in AN-induced tubular apoptosis and 
tubulointerstitial fibrosis by suppressing oxidative stress 
and interstitial cell proliferation. Our in vitro and in vivo 
imaging data further reveal that these effects might be 
mediated by a paracrine mechanism.
RESULTS
Human iPS-MSCs preserve renal function in the 
short-term AN model
Progressive loss of renal function is one of the major 
manifestations in animals with AN [19]. To determine the 
impact of iPS-MSCs on renal function, we transplanted 
iPS-MSCs into an AN model of NOD/SCID mice induced 
by a single injection of 5.5 mg/kg body weight ADR. At 
day 7, an elevation of UACR and BUN accompanied by 
a loss of body weight, kidney weight and serum albumin 
were detected (Table 1). AN mice that received human 
iPS-MSC transfusion had significantly lower BUN 
levels and higher serum albumin along with a gain of 
body weight and kidney weight (Table 1). Compared to 
AN mice given vehicle injection, only a trend toward 
reduction in UACR was observed in AN mice given iPS-
MSC therapy (Table 1).
Human iPS-MSCs prevent tubular apoptosis and 
oxidative damage in the short-term AN model
As renal tubular apoptosis is frequently reported in 
adriamycin-induced nephrosis [20], we next determined 
whether iPS-MSCs played a role in preventing renal 
tubular programed cell death. TUNEL assay showed that 
a significant amount of cells predominantly residing in 
renal tubules underwent apoptosis after 7 days of ADR 
injection, while iPS-MSCs remarkably rescued these 
cells from apoptosis (Figure 1A and 1B). There was 
less positive staining of 8-OHdG, an oxidative stress 
marker, in renal tubules of the iPS-MSCs treated group 
(Figure 1C and 1D). To elucidate the molecular basis 
of the anti-apoptotic effect elicited by iPS-MSCs, we 
detected survival and pro-apoptotic gene expressions in 
the renal cortex. Downregulated expression of survivin 
protein in AN was rescued by iPS-MSCs (Figure 1E 
and 1F). We next performed real-time PCR and Western 
blot to quantify the mRNA and protein expression of 
selected apoptotic genes. As shown in Figure 1G, AN 
triggered overexpression of Bax and downregulation 
of survivin mRNA in renal cortical tissues, and iPS-
MSCs significantly reverted these molecular changes. 
The protein induction of Bax in ADR-injured kidneys 
was also prevented by iPS-MSCs (Figure 1H and 1I). 
In addition, iPS-MSCs reduced Bax/Bcl2 ratio at both 
transcriptional and translational levels in AN mice 
(Figure 1G–1K).
Conditioned medium from human iPS-MSCs 
ameliorates proximal tubular apoptosis and 
oxidative stress induced by albumin overload in 
vitro
Because renal tubular epithelium was the primary 
site where iPS-MSCs exerted their anti-apoptotic effect 
according to our in vivo data, we speculated that renal 
proximal tubular epithelial cells (PTECs) might be 
the target cells that directly benefited from iPS-MSC 
therapy. We tested this hypothesis by incubating human 
PTECs with 48-h conditioned medium collected from 
iPS-MSCs (iPSMSC-CM) challenged with albumin-
overload. Consistent with the in vivo data, the degree of 
PTEC apoptosis induced by albumin was significantly 
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attenuated in the presence of iPSMSC-CM by manually 
counting the TUNEL positive cells (Figure 2A and 2B). 
Of particular interest, MTT assay demonstrated that the 
impairment of tubular proliferation induced by albumin 
load was also rescued by iPSMSC-CM (Figure 2C), 
implying a dual role of iPSMSCs in regulating tubular 
apoptosis and proliferation. To measure oxidative stress 
in PTECs, we labeled the cells with a fluorescent probe 
CM-H2DCFDA. In line with the anti-oxidative action of 
iPS-MSCs observed in vivo, iPSMSC-CM significantly 
hampered the robust generation of ROS induced by 
human serum albumin (HSA) in PTECs (Figure 2D). In 
addition, iPSMSC-CM substantially inhibited tubular 
overexpression of Bax mRNA and downregulation of 
Bcl2 mRNA and hence reduced the upregulated Bax/Bcl2 
ratio elicited by HSA (Figure 2E). Finally, iPSMSC-CM 
restored survivin mRNA expression under the albumin 
overloaded milieu (Figure 2E).
Human iPS-MSCs limit renal function decline 
and morphological changes of renal cortex in the 
long-term AN model
As chronic exposure of mice to ADR leads to 
progressive decline in renal function and destruction 
of renal tubules characterized by tubulointerstitial 
fibrosis [19], we sought to explore the therapeutic 
effect of iPS-MSCs on these aspects in the long-term 
AN model. Initially, we employed a dose of 5.5 mg/kg 
ADR to create a long-term model but most of the NOD/
SCID mice were unable to survive >10 days with this 
dosage (data not shown). When the dose was reduced 
to 4.0 mg/kg, all mice remained viable for 28 days. The 
experimental design was depicted in Figure 3A. Similar 
to previous study on SCID mice [21], body weight of 
NOD/SCID mice given the lower dose of ADR injection 
dropped progressively over the first 9 days, reaching 
a nadir by day 9, and then steadily increased, though 
not reaching baseline (Figure 3B). Starting from day 
7, multiple injections of iPS-MSCs at weekly intervals 
significantly prevented the loss of body weight in AN 
mice (Figure 3B). Loss of kidney weight induced by 
ADR was also prevented by iPS-MSCs (Table 2). At day 
28, ADR-injected mice developed functional features of 
chronic kidney disease including proteinuria, elevated 
serum creatinine and BUN, and hypertension (Table 2). 
Although a mild effect on UACR was observed, iPS-
MSCs therapy markedly brought the elevated serum 
creatinine, BUN and systolic blood pressure down to the 
baseline level in AN mice (Table 2). Morphologically, 
iPS-MSCs reduced renal tubular damage in the long-term 
AN model (Figure 3C and 3D).
Table 1: Physical and biochemical parameters of experimental animals (at day 7 of 5.5 mg/kg ADR injection)
Parameters Ctrl (n=5) iPS-MSCs (n=5) ADR (n=6) ADR+iPS-MSCs 
(n=5)
Body weight (g)
baseline 27.1±2.0 25.5±2.2 25.0±1.0 25.4±2.2
day 7 27.5±1.1 27.6±2.1 18.7±1.8a 21±1.6b
Kidney weight (mg)
right 189.4±22.9 204.7±24.4 146.5±12.3a 162.5±12.4b
left 178.6±20.3 194.1±17.6 135.7±11.9a 149.7±7.5b
UACR (ug/mg)
baseline 41.2±6.8 46.5±10.1 45.3±10.5 42.5±7.5
day 7 51.9±28.7 43.5±8.8 1393.0±1594.0 197±142.3
BUN (mg/dl)
baseline 21.3±1.0 20.9±3.0 21.8±1.2 21.6±2.0
day 7 19.0±1.5 18.5±1.3 25.1±3.6a 17.5±1.8b
Serum albumin (g/l)
baseline 70.0±4.0 67.9±4.4 63.8±7.0 69.9±5.8
day 7 68.5±6.5 67.0±4.6 26.8±6.2a 39.9±11.3b
UACR: urinary albumin-to-creatinine ratio; BUN: blood urea nitrogen.
ap<0.05 versus corresponding Ctrl group
bp<0.05 versus corresponding ADR group
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Figure 1: iPS-MSCs reduced tubular apoptosis and oxidative damage in murine adriamycin nephropathy (AN). (A) 
TUNEL-positive cells (arrows) revealing tubular apoptosis in mouse kidney at day 7 of ADR injection. (B) Quantification of apoptotic 
cells in renal cortex. n=5 per group. (C) Representative micrographs of 8-OHdG staining demonstrated that ADR-induced oxidative 
damage was attenuated by iPS-MSCs. Original magnification ×400. (D) Quantitative analysis of 8-OHdG staining. n=5 per group. (E) 
Immunohistochemical staining of survivin protein. Original magnification ×400. (F) Quantitative data of survivin staining. n=5 per group. 
(G) Quantitative determination of pro-apoptotic and survival gene expression in renal cortex at day 7 by real-time PCR. Protein expression 
was assessed by Western blot. Representative micrograph (H) and quantitative data (I-K) were shown. n=5 per group. **p<0.01 and 
***p<0.001 versus Ctrl; #p<0.05 and ##p<0.01 versus ADR.
Oncotarget103644www.impactjournals.com/oncotarget
Figure 2: iPS-MSCs reduced apoptosis, potentiated proliferation and attenuated oxidative stress in albumin overloaded 
PTECs. PTECs were treated with 10mg/ml human serum albumin (HSA) for 3 days in standard medium or medium supplemented with 
20% iPSMSC-CM. TUNEL assay indicated that iPSMSC-CM reduced the number of apoptotic tubular cells upon albumin challenge. 
Representative graphs (A) and quantification (B) were presented. n=6 from three independent experiments. (C) MTT assay: cells were 
incubated with 10 mg/ml HSA for 1 day in standard medium or medium supplemented with 10%, 20% or 50% iPSMSC-CM. n=6 from 
three independent experiments. (D) Oxidative stress assay determined by absorbance of CM-H2DCFDA. Green signals indicate retention 
of CM-H2DCFDA in tubular cells. Original magnification ×400. (E) Pro-apoptotic and anti-apoptotic genes detected by real-time PCR. 
Data were obtained from three independent experiments. ***p<0.001 versus NIL or vehicle; #p<0.01, ##p<0.01 and ###p<0.001 versus HSA.
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Human iPS-MSCs attenuate tubulointerstitial 
fibrosis in the long-term AN model
To examine the possible anti-fibrotic action of iPS-
MSCs on AN, we performed picrosirius red staining to 
characterize collagen deposition in the tubulointerstitium. 
A vast area of renal fibrosis was observed in ADR injected 
mice. Repeated iPS-MSCs administration significantly 
reduced the severity of fibrosis (Figure 3E and 3F). These 
results were further confirmed by Masson's Trichrome 
staining (Figure 3G and 3H). To characterize further 
the deposited proteins of interstitial fibrosis, we stained 
Figure 3: iPS-MSC treatment maintained tubulointerstitial architecture in renal cortex during AN injury. (A) Schematic 
diagram of experimental design. (B) Body weight was measured from each indicated time point. n=6 for Ctrl, n=5 for iPS-MSCs, n=8 for 
ADR and n=7 for ADR+iPS-MSCs. (C) PAS staining showed that tubular damage in ADR mice was prevented by iPS-MSC therapy. (D) 
Quantification of tubular injury. Tubular injury was assessed by the percentage of tubular dilatation, cast formation and loss of brush border. 
Scoring was performed on 10 high power fields from each mouse in an observer-blinded fashion. (E) Picrosirius red staining indicated 
amelioration of tubulointerstitial fibrosis in ADR mice after iPS-MSCs infusion. (F) Quantification of collagen deposition in tubular 
interstitium (Picrosirius red staining). Data were expressed as percentage of fibrotic area (stained in red). (G) Representative micrograph of 
Masson’s Trichrome staining. (H) Quantification of collagen deposition in tubular interstitium (Masson’s Trichrome staining). Data were 
expressed as percentage of fibrotic area (stained in blue). n=5 for Ctrl, n=8 for ADR and n=7 for ADR+iPS-MSCs. **p<0.01 and ***p<0.001 
versus Ctrl; #p<0.05, ##p<0.01 and ###p<0.001 versus ADR.
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sections for the fibrotic markers αSMA, collagen I and 
collagen IV. There is a greater positive staining of these 
markers in AN mice compared with control animals, which 
was attenuated by iPS-MSC therapy (Figure 4A–4F). 
Real-time PCR and Western blot analysis demonstrated 
that the overexpression of αSMA and collagen IV (mRNA 
and protein) in renal cortex of AN mice were markedly 
suppressed by iPS-MSCs (Figure 4G–4J).
Inhibition of hedgehog signaling in 
myofibroblasts contributes to the anti-fibrotic 
effect of iPS-MSCs in long-term AN
Interstitial myofibroblast proliferation and 
differentiation arising from activation of hedgehog 
signaling has been recently linked to kidney fibrosis 
in a variety of animal models [22, 23]. To investigate 
whether the anti-fibrotic action of iPS-MSCs was 
mediated by modulating this signaling pathway, we 
detected the expression of Shh, Ptch2 and Gli1, the key 
component genes from hedgehog signaling, in renal 
cortical lysates. ADR-induced overexpression of Shh, 
Ptch2 and Gli1 mRNA was significantly inhibited by 
iPS-MSCs (Figure 5A). This brought about reduced 
expression of proliferative genes including Ki67 and 
PCNA in AN mice that received iPS-MSC transfusion 
compared with the untreated AN group (Figure 5A). 
Moreover, we further showed that overexpression of 
PCNA protein from the renal cortex of AN mice was 
markedly attenuated by iPS-MSCs (Figure 5B and 
5C). By immunohistochemical staining, Ki67+ cells 
were mainly localized to the interstitial area and iPS-
MSC treatment significantly reduced the number of 
Ki67+ cells (Figure 5D and 5E). As previous study 
in AN model has demonstrated that Ki67+ cells are 
activated myofibroblasts residing within the renal 
tubulointerstitium [22], our data indicated that iPS-
MSCs might inhibit myofibroblast proliferation by 
deactivating hedgehog signaling. To further elucidate 
the mechanism, we devised an in vitro co-culture system 
that physically separates two cell types but allows cell-
to-cell communication through secreting factors (Figure 
5F). In this system, we showed that albumin overload 
induced Shh mRNA (a ligand of the hedgehog signaling 
pathway) in a proximal tubular cell line NRK52E and 
Gli1 mRNA (an effector gene of hedgehog signaling 
pathway) overexpression in a fibroblast cell line 
NRK49F (Figure 5G and 5H). When iPSMSC-CM was 
Table 2: Physical and biochemical parameters of experimental animals (at day 28 of 4.0mg/kg ADR injection)
Parameters Ctrl (n=7) iPS-MSCs (n=8) ADR (n=8) ADR+iPS-MSCs (n=7)
Kidney weight (mg)
right 221.9±28.7 211.9±18.5 153.5±12.1a 192.0±21.0b
left 195.0±26.6 199.6±18.6 146.3±9.2a 183.9±17.3b
UACR (ug/mg)
baseline 56.3±19.0 42.4±7.7 41.9±9.0 40.4±7.0
day 28 32.5±2.3 39.3±12.0 547.4±359.7 428.9±176.0
BUN (mg/dl)
baseline 18.3±4.3 18.3±3.0 18.2±1.4 17.8±1.7
day 28 17.7±1.3 17.1±0.9 21.2±3.3a 17.6±2.1b
SCr (mg/dl)
baseline 0.33±0.10 0.35±0.07 0.30±0.10 0.26±0.08
day 28 0.32±0.16 0.30±0.12 0.56±0.21a 0.23±0.16b
SBP (mmHg)
baseline 110.7±7.3 112.3±3.7 111.2±4.2 109.6±3.1
day 28 110.1±7.2 111.2±3.2 127.2±15.5a 112.3±13.9b
sTSG-6 (pg/ml)
day 28 13.7±4.9 19.0±17.2 39.7±14.6a 34.6±16.5
UACR: urinary albumin-to-creatinine ratio; BUN: blood urea nitrogen; SCr: serum creatinine; SBP: systolic blood pressure; 
sTSG-6: serum TSG-6.
ap<0.05 versus corresponding Ctrl group
bp<0.05 versus corresponding ADR group
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introduced to the system, both genes were significantly 
downregulated (Figure 5G and 5H). In addition, 
iPSMSC-CM partially blocked the overexpression of 
fibrotic gene aSMA in NRK49F. This data supports a 
Figure 4: iPS-MSCs attenuated interstitial fibrosis in AN mice. (A) Representative micrograph of immunohistochemical collagen 
IV staining, original magnification ×400. (B) Quantification of collagen IV staining. Eight field of views per slide were counted and data 
were expressed as IOD. Mice received PBS serve as control (Ctrl). (C), (D) Representative photomicrographs and quantification of collagen 
I protein. Original magnification ×400. (E), (F) Immunohistochemical staining and quantification of αSMA protein in tubulointerstitium. 
Original magnification ×400. n=5 for Ctrl, n=8 for ADR and n=7 for ADR+iPS-MSCs. ***p<0.001 versus Ctrl; #p<0.05, ##p<0.01 and 
###p<0.001 versus ADR. (G) Western blot of pro-fibrotic proteins in renal cortex. (H), (I) Quantitative analysis of renal cortical collagen 
IV and αSMA protein expression. (J) Real-time PCR analysis of fibrotic genes in renal cortex. Ctrl: n=5; iPS-MSCs: n=5; ADR: n=8; and 
ADR+iPS-MSCs: n=7. ***p<0.001 versus Ctrl; #p<0.05 and ##p<0.01 versus ADR.
Oncotarget103648www.impactjournals.com/oncotarget
paracrine mechanism of iPS-MSC in modulating fibrotic 
response by interrupting the tubulo-interstitial crosstalk.
iPS-MSCs are entrapped in the lungs after 
intravenous administration
To track the fate of stem cells after intravenous 
injection, we examined human gene expression in various 
tissues from NOD/SCID mice. Human POLR2E specific 
primers were used according to a previous study [24], 
Human POLR2E was mostly expressed in the lungs at 
4 h of iPS-MSC transfusion (Figure 6A). To rule out the 
possibility of false negative signals from a low expression 
level of POLR2E gene in iPS-MSCs, we further confirmed 
the results with specific primers for human FN, a gene 
expressed more abundantly in iPS-MSCs. Again, the lung 
was the main tissue where FN expression was detected at 
4 h of iPS-MSCs injection, and its expression persisted 
for 24 h albeit to a much lesser extent, and disappeared 
after 3 days (Figure 6A). Expression of either human 
POLR2E or FN was not detected in the right (Figure 6A) 
or left (Figure 6B) kidneys. In addition, in vivo imaging 
confirmed that the distribution of DiR-labeled iPS-MSCs 
was mainly confined to pleurae and no signal was detected 
at the site of the kidneys for up to 7 days after injection 
(Figure 6C). It has been shown that the protective effect 
of BM-MSC in myocardial infarction was mediated by 
TSG-6 whose release was activated when BM-MSCs 
were trapped in lung [25]. To examine whether the same 
mechanism applies to our models, we measured the serum 
TSG-6 level for all groups of mice at endpoint. Our data 
showed that serum TSG-6 molecule was not significantly 
elevated after repeated iPS-MSCs treatments (Table 2). 
Instead, we observed a remarkable elevation of TSG-6 
after ADR treatment. This data indicated that TSG-6 might 
not be a potential candidate mediating the renoprotective 
effect of iPS-MSCs.
DISCUSSION
Knowledge on the therapeutic use of MSCs in 
kidney diseases is growing rapidly in recent years. As a 
more robust cell replacement candidate, iPS-MSCs have 
been demonstrated to be effective in various types of 
diseases [11–18]. Thus far, however, little is known about 
the potential effect of iPS-MSCs in attenuating renal 
dysfunction and kidney damage due to acute or chronic 
injuries. We herein extended the application of iPS-MSCs 
to an animal model of AN. Our study is the first to report 
the capability of human iPS-MSCs in reversing ADR-
induced acute and chronic kidney injury at multiple levels, 
including preserving renal function, limiting tubular 
apoptosis at the acute phase and reducing tubulointerstitial 
fibrosis at the chronic phase. We also delineated that 
ablation of intracellular oxidative stress and interruption 
of hedgehog signaling might be mechanistically related 
to the anti-apoptotic and anti-fibrotic effects exerted by 
iPS-MSCs.
Adriamycin-induced nephropathy in mice is 
reported to be an excellent model commonly used for 
pharmacological intervention studies by virtue of its 
capability to recapitulate the cardinal features of kidney 
disease including biochemical changes in serum and urine, 
morphologic features of glomerulosclerosis, and clinical 
nephrosis [26]. It is also a prevailing model to test the 
efficacy of stem cells on kidney disease in the past decade 
[27–29]. To circumvent the issue of immunorejection of 
exogenous human cells in mice, we chose to establish AN 
in NOD/SCID mice. We showed that a dose of 5.5 mg/
kg ADR after 7 days ’ exposure and 4.0 mg/kg after 28 
days’ exposure significantly induced albuminuria, and 
elevations in serum creatinine and BUN. The capability 
of iPS-MSCs to mitigate renal dysfunction in AN was 
associated with a prevention of body weight and kidney 
weight loss at 7 days and 28 days as well as hypertension 
at 28 days, strengthening a genuine renoprotective role 
of iPS-MSCs. However, iPS-MSCs failed to attenuate 
albuminuria in both models, although an insignificant 
trend was observed. This might be ascribed to a limited 
recovery of the insult to the glomerular endothelium, a 
primary target of ADR-mediated renal injury [30], which 
forms an integral component of the glomerular filtration 
barrier against protein leakage. Indeed, we found no 
significant discrepancy in the extent of glomerular damage 
in AN mice between iPS-MSCs treated and untreated 
groups (data not shown). This lack of anti-proteinuric 
effect was also documented by other groups using other 
sources of stem cells in this model [27, 28].
We have previously established the pivotal? role of 
tubular epithelial cells in orchestrating tubulointerstitial 
damage in proteinuric kidney diseases [31–33]. In AN, 
tubular apoptosis was shown to emerge as early as 7 
days after adriamycin injection [20]. Consistent with this 
finding, our 7-day AN model displayed markedly more 
apoptotic cells mainly located in the tubular epithelium, 
and iPS-MSCs significantly attenuated tubular apoptosis. 
This anti-apoptotic effect was accompanied by decreased 
Bax expression, Bax/Bcl2 ratio and a restoration of 
survivin loss in the renal cortex of AN mice, suggesting 
that the intrinsic apoptotic signaling pathway might 
be intercepted by iPS-MSCs. In vitro, iPSMSC-CM 
remarkably limited PTEC apoptosis and promoted 
PTEC survival under albumin overloaded condition, 
with a substantial rescue of the abnormal expression of 
pro-apoptotic and survival genes. This anti-apoptotic 
action of iPS-MSCs on tubular cells might be attributed 
to the alleviation of oxidative stress as evidenced by our 
in vivo and in vitro finding that tubular ROS activation 
was dramatically inhibited by iPS-MSCs. As tubular 
apoptosis is a predominant cellular event commonly 
observed in various types of acute kidney disease models 
regardless of the primary insult [34], the tubular anti-
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Figure 5: iPS-MSCs modulated fibroblast activation by attenuating hedgehog signaling pathway. (A) Real-time PCR of Shh, 
Ptch2, Gli1, Ki67, and PCNA expression in the kidneys at 28 days of ADR injection (Ctrl: n=5; iPS-MSCs: n=5; ADR: n=8; and ADR+iPS-
MSCs: n=7). (B), (C) Western blot to detect PCNA expression in renal cortex and its quantification. (D), (E) Immunohistochemical staining 
and quantification of Ki67 expression in tubulointerstitium. n=5 for Ctrl, n=8 for ADR and n=7 for ADR+iPS-MSCs. (F) Co-culture 
design to test the interaction of NRK52E and NRK49F and the role of iPS-MSC conditioned medium. (G). Real-time PCR of Shh mRNA 
expression in NRK52E (n=3). (H). Real-time PCR of Gli1 and αSMA mRNA in NRK49F collected from co-culture. Data were collected 
from three independent experiments. **p<0.01 versus Ctrl; #p<0.05 and ##p<0.01 versus ADR.
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apoptotic effect mediated by iPS-MSCs observed here 
might provide insights on the potential application of 
iPS-MSCs in other AKI models.
Another significant finding here is that 
tubulointerstitial fibrosis caused by ADR was also 
prevented by iPS-MSCs. This is reflected by the reduction 
Figure 6: Stem cell tracking revealed trapping of iPS-MSCs in the lungs after intravenous injection. (A) Representative 
agarose gels showing the expression of human POLR2E and FN mRNA in mouse heart, liver, spleen, lung, and right kidney by using 
specific primers. Data were representatives of 3 mice from each time point. (B) RT-PCR showing human FN mRNA expression in mouse 
left kidney at four different time points after iPS-MSC injection. Numbers (1-2) indicate individual mouse in a given group. (C) In vivo 
imaging of NOD/SCID mice. Mice were injected with unlabeled iPS-MSCs (left) or DiR-labeled iPS-MSCs (right).
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of cortical deposition of total collagen at day 28 of ADR 
injection in mice treated with iPS-MSCs. Indeed, iPS-
MSCs also interrupted the synthesis of extracellular 
matrix proteins such as collagen I and IV and reduced the 
expression of the myofibroblast marker αSMA. Previous 
cell-based therapies in AN have focused on the beneficial 
effect of stem cells on glomerular damage. For example, 
Manasco A. et al reported that MSCs reduced apoptosis 
of podocytes in chronic AN [27]. Similarly, Zoja C.et al 
proposed that glomerular podocytes and progenitor cells 
are the potential cellular targets for MSCs to exert their 
reparatory effect [28]. As renal function deterioration 
correlated better with the extent of tubulointerstitial 
damage than that of glomerular changes [35, 36], the 
anti-fibrotic effect of iPS-MSCs reported here may have 
provided another explanation for the recovery of renal 
function after stem cell injection.
It has long been considered that epithelial-to-
mesenchymal transition contributes significantly to tissue 
fibrosis [37], only to be questioned by recent studies [38, 
39]. Interestingly, a theory of tubulointerstitial cross-
talk has been proposed recently [40, 41]. This theory 
highlighted that signaling molecules secreted from tubular 
epithelial cells activate interstitial myofibroblasts to 
proliferate and secrete extracellular matrix proteins [42]. 
In this context, hedgehog signaling was heavily implicated 
in modulating myofibroblast activation in chronic kidney 
diseases [43]. Here, we showed in vivo that iPS-MSCs 
significantly attenuated the expression of several critical 
components of hedgehog signaling, and downregulated 
proliferative protein expression. Immunostaining of Ki67 
defines the interstitial localization of proliferating cells of 
probable myofibroblast origin. These findings demonstrate 
the anti-fibrotic role of iPS-MSCs to be mediated via 
attenuation of the hedgehog signaling pathway.
The molecular mechanism of how iPS-MSCs 
suppress oxidative stress and hedgehog signaling in AN 
remains unknown. A possible explanation is that iPS-MSC 
might secrete paracrine factors into the blood stream that 
act on proximal tubule to mitigate the aberrant induction 
of oxidative stress and hedgehog signaling pathway. This 
paracrine hypothesis has been supported by many other 
studies using iPS-MSCs [11-13, 17]. Our in vitro data also 
partially supported this mechanism as conditioned medium 
from iPS-MSCs exerted similar effects on reducing oxidative 
stress and thus tubular apoptosis. In addition, our molecular 
tracking technology combined with in vivo imaging showed 
that most of the iPS-MSCs after infusion were trapped in 
the lungs, and could not be detected in the kidney at any 
given time point. This observation is in accordance with a 
previous study showing an absence of transplanted MSCs in 
the kidney without undermining their effect on ischemic AKI 
[44]. Indeed, this lung barrier phenomenon for intravenous 
cell transplantation has been documented extensively in the 
literature [45]. Pulmonary entrapment would probably reduce 
the number of stem cells homing to non-pulmonary tissues 
such as the kidney and therefore it was initially regarded as 
a big obstacle to overcome in the field of cell-based therapy. 
Nevertheless, a later study on myocardial infarction showed 
that hMSCs embolized to the lungs were activated to secrete 
TSG-6, an anti-inflammatory factor accounting for their 
protective effect on the infarcted heart [25]. A more recent 
study also supported this theory in that pulmonary entrapment 
was a prerequisite for MSCs to exert their beneficial effect on 
peritoneal adhesion via TSG-6 [46]. As the secretome profile 
of iPS-MSCs is different from BM-MSCs [17], it remains 
unclear if TSG-6 is a key factor modulating oxidative stress 
and hedgehog signaling in AN. Indeed, we observed no 
elevated level of TSG-6 after multiple injection of iPS-MSCs. 
Since our in vitro data strongly suggest a paracrine action of 
iPS-MSCs on various kidney cell types (e.g. tubular cells and 
fibroblast), the exact renotrophic molecule(s) secreted by iPS-
MSCs in vivo will merit further definition.
The tumorigenicity and immunogenicity of iPS 
cells have brought great concerns regarding their safety 
in clinical application [47, 48]. Some previous studies 
reported no signs of tumor formation when using iPS cell 
derivatives on other disease models [49, 50], indicating 
a lower tumorigenicity of the iPS cell derivatives than 
their parental iPS cells. Consistently, we observed no 
teratoma formation in this study as well as in our previous 
application of iPS-MSCs on another disease model 
[11], despite injection of cells into immunodeficient 
mice. However, 4 weeks’ observation is obviously not 
long enough to fully assess the tumorigenic potential 
of iPS-MSCs, and hence long-term evaluation is still 
required. In addition, this study was not able to assess the 
immunogenicity of iPS-MSCs in vivo due to the limitation 
of the existing model that applied exogenous human 
cells to immunodeficient mice. Although the remarkable 
inhibition of NK-cell proliferation and cytolytic function 
of iPS-MSCs [51] implied that these cells might be 
immune-privileged, the issue of immuno-rejection should 
be addressed by further studies before these cells can be 
clinically used in patients with kidney diseases.
In summary, we have provided novel data to support 
a reparatory effect of iPS-MSCs in ameliorating renal 
tubular apoptosis and interstitial fibrosis in murine AN. This 
is likely mediated by modulation of oxidative stress and 
hedgehog signaling through a paracrine mechanism. The 
anti-apoptotic and anti-fibrotic effects of iPS-MSCs warrant 
confirmation in other models of AKI or CKD, which could 
hold promise for a novel therapeutic approach in humans.
MATERIALS AND METHODS
Human iPS-MSCs preparation and conditioned 
medium collection
N1-iPS-MSC clone was used in this study. This 
clone was generated from iPSCs reprogramed from 
human fibroblasts via viral transduction with human 
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cDNAs of Klf4, Sox2, Oct4, and c-Myc as described in 
our previous studies [15, 52]. MSCs were derived from 
iPSCs according to our established protocol [11]. In brief, 
iPSCs were differentiated under feeder-free condition and 
in DMEM medium containing 10% FCS, 10 ng/ml bFGF, 
10 ng/ml PDGF, and 10 ng/ml EGF. MSCs were purified 
by cell sorting of CD105+/CD24-. We have verified the 
identity of these iPS-MSCs in our previous studies by 
detecting the surface marker expression and assessing 
their differentiation capacities [11, 15, 52]. The resulting 
iPS-MSCs closely resemble BM-MSCs in many regards, 
including the capacity of differentiation into osteoblasts, 
chrondrocytes and adipocytes and the expression of surface 
antigens such as CD44, CD49a and e, CD73, CD105, and 
CD166 [11, 15, 52]. iPS-MSCs within the ninth passages 
were used throughout this study. To collect the conditioned 
medium, iPS-MSCs with 70%–80% confluency were re-
fed with serum-free DMEM supplemented with antibiotics. 
Conditioned media were harvested after 48-h incubation, 
centrifuged at 1000g for 5 min to remove detached cells and 
stored at −80°C until future use.
Cell lines
Human primary PTECs were obtained from Lonza 
(Walkersville, MD, USA). The cells were cultured in Renal 
Epithelial Cell Growth Medium (REGM) from Lonza 
at 37°C in 5% CO2 and 95% air. Rat tubular epithelial 
cell line NRK52E and fibroblast cell line NRK49F were 
purchased from American Type Culture Collection (ATCC, 
Manassas, VA, USA), and maintained in DMEM/F12 
medium supplemented with 5% fetal calf serum (FCS). In 
all experiments, there was a ‘growth arrest’ period of 24 hr 
in serum-free medium prior to stimulation.
Detection of intracellular reactive oxygen species 
(ROS)
Detection of ROS was performed as previously 
described [17]. Briefly, PTECs were plated at 2×104 
cells/chamber on 8-well chamber slides (Nunc Lab-Tek 
II, Thermo Scientific) and then treated with HSA, 20% 
iPSMSC-CM, and HSA with 20% iPSMSC-CM. Cells in 
serum-free medium were served as normal control (NIL). 
After 24-h incubation, cells were washed with PBS and 
incubated with an oxidative fluorescence probe 5-(and 6-) 
chloromethyl-2’, 7’-dichlorodihydrofluorescein diacetate 
(CM-H2DCFDA, Life Technologies, Carlsbad, CA, USA) 
for 45 min, followed by three rounds of PBS wash and 
then fixed with 4% paraformaldehyde. Green fluorescent 
signal was visualized with a fluorescence microscope.
Total RNA extraction and real-time PCR
Total RNA was extracted using Trizol RNA isolation 
reagent (Life Technologies). Reverse transcription was 
carried out by using High Capacity cDNA Reverse 
Transcription Kits (Applied Biosystems, Foster City, 
USA). Real-time PCR was performed on an ABI Prism 
7500 sequence detection system (Applied Biosystems) 
using specific primers designed from known sequences in 
the GenBank. The primer pairs for different genes were 
shown in Supplementary Table 1. The mRNA level of 
various genes was analyzed by the SDS software (Applied 
Biosystems) and target values were normalized to β-actin 
mRNA using relative quantification method.
Western blot analysis
Kidney tissues were homogenized and lysed 
with RIPA lysis buffer (Millipore, Bedford, MA, 
USA) containing protease inhibitor cocktails (Sigma, 
St Louis, MO, USA) on ice. Protein was collected 
after centrifugation at 12,000g and concentration was 
determined by Pierce BCA method (Thermo Scientific, 
Rockford, IL, USA). Twenty micrograms of total protein 
were electrophoresed through a 4-12% Bolt® Bis-Tris 
Plus gradient gel (Life Technologies) before transferring 
to a 0.2 μm PVDF membrane. The primary antibodies 
used in this assay were: Anti-Bax from Cell Signaling 
Technology (Beverly, CA, USA), anti-collagen IV 
antibodies from Abcam (Cambridge, UK), anti-αSMA 
from Sigma Aldrich (St Louis, MO, USA), anti-PCNA 
from Santa Cruz Biotechnology (Santa Cruz, CA, USA) 
and anti-β-actin from Lab Vision (Fremont, CA, USA). 
The membrane was incubated by secondary antibodies 
(Dako, Glostrup, Denmark) and detected by ChemiDoc 
imaging system (Bio-Rad, Hercules, CA, USA).
Animal studies
This study was approved by the Committee on 
the Use of Live Animals in Teaching and Research of 
The University of Hong Kong and was performed in 
accordance with the National Institute of Health Guide 
for Care and Use of Laboratory Animals. Seven- to 
eight-week old NOD/SCID mice were obtained from the 
laboratory animal unit of the University of Hong Kong. 
Dose finding experiment defined an optimal dose of 5.5 
mg/kg body weight of adriamycin (Pharmachemie BV, 
Netherlands) for short-term AN model and 4.0 mg/kg 
body weight of ADR for long-term AN model. For short-
term acute model, AN was induced by single injection 
of 5.5 mg/kg ADR via tail vein. 2×105 iPS-MSCs were 
administered intravenously at 2 hr after AN injection. 
Mice were sacrificed at day 7 of ADR injection. For long-
term chronic model, AN was created by single injection 
of 4.0 mg/kg ADR via tail vein. iPS-MSCs (2×105 cells/
mouse) were injected intravenously into NOD/SCID mice 
with or without AN at 2 hr, and -repeated on day 7, day 
14 and day 21 of ADR injection. Systemic blood pressure 
was measured by tail-cuff method. Mice were sacrificed 
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at day 28 of ADR injection. 24-h urine samples from each 
group were collected by metabolic cages with access to 
food and water. Urinary albumin was measured by ELISA 
quantitation kit (Bethyl Laboratories, Montgomery, 
AL, USA). Blood urea nitrogen (BUN), urine and 
serum creatinine were determined by enzymatic method 
(Stanbio Laboratory, Boerne, TX, USA). Serum TSG-
6 was measured by commercial ELISA kit (CUSABIO, 
MD, USA). Right and left kidneys from each group were 
collected, weighted and halved by surgical knife. One half 
was used for mRNA and protein collected. The other half 
was fixed on 10% neutral buffered formalin. Expression 
of pro-apoptotic and pro-fibrotic genes were assessed by 
real-time PCR and Western Blot.
TUNEL assay
Apoptotic cells were evaluated by labeling and 
measuring DNA strand breaks in TUNEL method with 
an in situ cell death detection kit (Millipore) as per the 
manufacturer's manual. For paraffin-embedded kidney 
sections, apoptotic cells with positive staining were 
counted in 8 high-power fields (HPF) per slide. To 
detect tubular apoptosis under albumin challenge in vitro, 
PTECs at 2×104 cells/chamber were seeded onto 8-well 
glass chamber slides and incubated for 3 days in medium 
alone, 20% iPSMSC-CM (v/v), medium supplemented 
with 10mg/ml HSA and 10mg/ml HSA+ 20% iPSMSC-
CM. Apoptotic PTECs were counted in 8 high-power 
fields per group. Data were expressed with number of 
positive cells/HPF.
Morphological assessment
Morphological changes of the renal cortex were 
determined by PAS staining on paraffin embedded 
sections. Tubular injury was assessed by the percentage 
of tubular dilation, cast formation and loss of brush 
border. Scoring was performed on 10 field of views 
(magnification: 400×) from each mice and calculated as 
follows: 0, none; 1, ≤10%; 2, 11%–25%; 3, 26%–45%; 4, 
46%–75%; and 5, >76%. [53] Total collagen was detected 
by Picrosirus Red staining and Masson’s Trichrome 
staining kits (Sigma Aldrich).
Immunohistochemistry
Immunohistochemistry was performed as 
previously described in paraffin-embedded tissue 
sections at a thickness of 4 μm [54]. The primary 
antibodies against 8-OHdG (Santa Cruz), survivin (Cell 
Signaling Technology), collagen IV (Abcam), collagen I 
(Abcam), αSMA (Santa Cruz), and Ki67 (Abcam) were 
used. Sections were counterstained with hematoxylin. 
Positive staining was quantified in 8 equivalent cortical 
HPFs (400×) by Image Pro Plus Software 5.0 (Media 
Cybernetics, Silver Spring, USA) and presented as 
integrated optical density (IOD).
Co-culture set up and experimental conditions
NRK52E cells were seeded onto the 12-well 
transwell cassette (Corning, Cambridge, MA, USA), and 
grown for 24 hr until confluence. NRK49F cells (1×105/
well) were cultured in the lower chamber of the Transwell 
plate. These two cell types were physically separated 
by a transwell insert (of 0.4 mm pore size). HSA was 
supplemented into the upper chamber of transwell and 
incubated with or without 20% iPSMSC-CM in the upper 
chamber. Following 24-h co-culture, NRK52E cells from 
the upper chamber and NRK49F cells from lower chamber 
were lysed, counted, and subjected to real-time PCR to 
determine gene expression.
Stem cell tracking
Total mRNA extracted from heart, liver, spleen and 
kidney at various time points were submitted to RT-PCR. 
The primer sequences specific for human POLR2E and 
human FN were listed in Supplementary Table 1. In vivo 
imaging was used to better visualize the tissue distribution 
of iPS-MSCs after transfusion. Briefly, 2×105 cells were 
labeled with DiR (PerkinElmer, Waltham, MA, USA) 
before intravenous transfusion into NOD/SCID mice. 
Unlabeled iPS-MSCs were served as negative control. The 
migration and accumulation of iPS-MSCs were visually 
depicted and analyzed with an in vivo imaging system 
(IVIS Spectrum, PerkinElmer) at indicated time points.
Statistical analysis
All data were expressed as means ± standard 
deviation unless otherwise specified. Statistical analysis 
was performed using GraphPad Prism v.5 for Windows 
(GraphPad Software Inc., San Diego, CA, USA). 
Differences between groups were determined using two-
tailed t test or one-way ANOVA with Tukey's multiple 
comparison test.P< 0.05 was considered statistically 
significant.
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